Interaksi Insulin aspart dan Sitagliptin dan metformin
Insulin aspart dan Sitagliptin dan metformin: kedua label peresepan menguraikan interaksi yang biasanya memerlukan pemantauan, perubahan dosis, atau pemberian jarak antardosis.
Biasanya dapat dikelola dengan pemantauan atau perubahan dosis. Beri tahu apoteker Anda bahwa Anda menggunakan keduanya.
Apa kata label FDA
Dari label Insulin aspart · berlaku sejak 2026-01-14
Increase frequency of glucose monitoring with changes to: insulin dosage, concomitantly administered glucose lowering medications, meal pattern, physical activity; and in patients with renal or hepatic impairments and hypoglycemia unawareness ( 5.
Risk Factors for Hypoglycemia The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal.
Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics.
Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,…
Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of Insulin Aspart Drugs: Alcohol, beta-blockers, clonidine, and lithium salts.
Dari label Sitagliptin dan metformin (JANUMET XR) · berlaku sejak 2026-08-11
Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues: Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue.
A lower dose of insulin or insulin secretagogue may be required.
Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues JANUMET XR may increase the risk of hypoglycemia when combined with insulin and/or an insulin secretagogue (e.g., sulfonylurea) [see Adverse Reactions (6) ] .
A lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with JANUMET XR [see Drug Interactions (7) ] .
Insulin Secretagogues or Insulin Clinical Impact: Coadministration of JANUMET XR with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia.
Menggunakan lebih dari dua obat ini? Interaksi saling bertumpuk. Periksa seluruh daftar Anda sekaligus; daftar itu tetap berada di peramban Anda.
Buka di pemeriksaBukan nasihat medis. Interaction Checker mengutip teks label FDA dan lembar fakta NIH. Penting atau tidaknya suatu interaksi bagi Anda bergantung pada dosis, waktu penggunaan, fungsi ginjal dan hati, serta kondisi lain. Pastikan dengan apoteker atau dokter yang meresepkan.